{"analyses":[{"ciLowerLimit":"0.95","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.99","estimateComment":"This reflects Week 7.","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.0022","pValueComment":"This reflects Week 7.","paramType":"Odds Ratio (OR)","paramValue":"0.97","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"236"}]}],"title":"Fast Metabolizers by Nicotine Metabolite Ratio"},{"categories":[{"measurements":[{"groupId":"OG000","value":"214"}]}],"title":"Slow Metabolizers by Nicotine Metabolite Ratio"}],"denoms":[{"counts":[{"groupId":"OG000","value":"450"}],"units":"Participants"}],"description":"Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.\n\nThe variants present in people in the slow genotype group include \\*17, \\*20, \\*23,\\*27, \\*35, \\*9, \\*2, \\*25, \\*26, and \\*4. The fast metabolizers have none of the variant alleles tested.\n\nBlood samples were collected for 3HC/COT ratio at Week 0.","groups":[{"description":"All study participants were African American adults and received either bupropion (150mg bid) for 7 weeks in addition to health education counseling or placebo for 7 weeks in addition to health education counseling.","id":"OG000","title":"All Study Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This variant is related to nicotine metabolism and was collected from all study participants but not analyzed by study arm as it does not relate to the study medication. Data pre-specified to be collected and reported as a single arm.","reportingStatus":"POSTED","timeFrame":"Weeks 0","title":"Number of Slow and Fast Metabolizers by Metabolite Ratio","type":"SECONDARY","unitOfMeasure":"Participants"}